(Q44616410)

4 December 2017

title

Generation and evaluation of a CYP2C9 heteroactivation pharmacophore (English)

1 reference

4 December 2017

Generation and Evaluation of a CYP2C9 Heteroactivation Pharmacophore (English)

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

author name string

Ann-Charlotte Egnell

1

1 reference

4 December 2017

Cecilia Eriksson

2

1 reference

4 December 2017

Nan Albertson

3

1 reference

4 December 2017

Brian Houston

4

1 reference

4 December 2017

Scott Boyer

5

1 reference

4 December 2017

language of work or name

English

0 references

publication date

13 October 2003

1 reference

full work available at URL

4 December 2017

https://syndication.highwire.org/content/doi/10.1124/jpet.103.054999

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Journal of Pharmacology and Experimental Therapeutics

21 March 2024

published in

1 reference

4 December 2017

volume

307

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

878-887

1 reference

Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis

4 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines

21 March 2024

2

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

3

29

30

2001

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Identification of common functional configurations among molecules

21 March 2024

4

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site

21 March 2024

6

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine

21 March 2024

8

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

9

28

994

2000

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach

21 March 2024

12

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding

21 March 2024

13

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

The mechanism of the interaction between amiodarone and warfarin in humans

21 March 2024

14

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Elucidation of distinct ligand binding sites for cytochrome P450 3A4

21 March 2024

15

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

16

28

246

2000

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

17

29

1029

2001

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements

21 March 2024

18

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations

21 March 2024

19

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

20

24

260

1996

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

22

24

1

1996

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 March 2024

23

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

24

29

1644

2001

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites

21 March 2024

26

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation

21 March 2024

27

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Schweizerische medizinische Wochenschrift

21 March 2024

28

122

1897

1992

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives

21 March 2024

29

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

The Substrate Binding Site of Human Liver Cytochrome P450 2C9: An Approach Using Designed Tienilic Acid Derivatives and Molecular Modeling

21 March 2024

30

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9

21 March 2024

31

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

32

27

1117

1999

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 March 2024

33

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

21 March 2024

34

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

21 March 2024

35

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions

21 March 2024

36

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA.

21 March 2024

37

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast

21 March 2024

38

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site

21 March 2024

39

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

21 March 2024

44

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

15 Reversible enzyme inhibition

21 March 2024

45

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

21 March 2024

47

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

48

28

360

2000

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

Alprazolam is another substrate for human cytochrome P450-3A isoforms.

21 March 2024

50

1 reference

https://api.crossref.org/works/10.1124/JPET.103.054999

21 March 2024

Identifiers

1 reference

4 December 2017

1 reference